At a glance
ClinicalIndex Comparison RecordN/AUnknown· 15 target
Drug / intervention
Rapamycindrug
Likely dose
Rapamycin 2mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Efficacy and Safety of Rapamycin in the Treatment of Crohn's Disease-related Stricture
The Second Hospital of Nanjing Medical University·interventional·Posted Feb 5, 2016·Updated Oct 8, 2020
In Brief
A clinical study evaluating Rapamycin for Crohn's Diseases. Targeting 15 participants across 1 site.
Detailed Summary
Crohn's disease （CD） with stenosis has limited therapeutic options and with high surgical rate. The present clinical trial aims to evaluate the efficacy and safety of rapamycin in the treatment of stricturing Crohn's Disease.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCrohn's Diseases
CountriesChina
Collaborators--
Timeline
N/AUnknownOverdue
201520162017201820192020202120222023202420252026
Enrollment StartApr 2015
First PostedFeb 2016
Primary CompletionOct 2020
TodayJul 2026
First PostedFeb 5, 2016
Enrollment StartApr 1, 2015
Primary CompletionOct 1, 2020
TodayJul 1, 2026
Enrollment to primary: 5.5 yearsPosted 10.4 years ago
Interventions
Rapamycindrug
Participants with gastrointestinal strictures were treated with rapamycin 2mg daily at least six months.